Pharmaceuticals News and Research

RSS

States uneasy about impact of Medicaid expansion

The expansion of insurance coverage under the health reform law is due largely to an expansion of the government-funded Medicaid program, which is causing some doctors to worry about the specifics of implementation, according to the New York Times. "Absorbing that many people into the system will not be easy. The program is administered and partly financed by the states, which are now racing to figure out how to carry out the necessary changes and simplify enrollment even as they struggle to cope with severe budget cuts and staff shortages."

28 Apr 2010

Actavis launches Tamsulosin capsules in the U.S.

Actavis Inc., today began shipping Tamsulosin capsules to its customers in the United States. The generic equivalent to Flomax®, Tamsulosin is used to treat benign prostatic hyperplasia (BPH). Actavis is partnering with Synthon Pharmaceuticals to launch and market Tamsulosin capsules in the United States.

28 Apr 2010

Expensive generic drugs cost Australia billions

Consumers and the Australian Government are paying up to 10 times more for generic cholesterol-lowering drugs compared to the United Kingdom, according to research carried out by health economists at the University of Sydney.

27 Apr 2010

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Antares Pharma, Inc., a leader in self-injection drug delivery technology and Uman Pharma, a manufacturer of top-quality injectable pharmaceutical products based in Quebec, Canada, today announced the formation of a strategic alliance covering Antares' VIBEX™ MTX.

27 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, announced today it has received new advertising approval from Shaanxi State Food and Drug Administration for marketing Xin Aoxing Oleanolic Acid Capsules.

27 Apr 2010

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that it will be presenting three separate presentations at the Cambridge Healthtech Institute's 4th Annual Antibacterial Drug Development Conference, Resistance is Futile: The Challenge of Antibacterial Drug Development, April 27 - 28, in San Diego, CA.

27 Apr 2010

ICON reports net revenues of $219 million for first-quarter 2010

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2010.

27 Apr 2010

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.

27 Apr 2010

European commission's FP7 programme allocated euro 6.10 billion

Europe is moving towards becoming a knowledge-based economy. Keeping in line with this objective, the European commission has instituted the Framework 7 (FP7) programme. Launched to support the re-launched Lisbon strategy, FP7 focuses on research themes rather than the framework programmes of the past. It has been designed to meet some of the persisting challenges of raising Europe to match global excellence in research, thereby benefiting the European life science funding.

27 Apr 2010

Initiative to lower amount of salt in American diet

The American Heart Association and the National Salt Reduction Initiative, a national collaboration led by the City of New York, share a common goal -- to gradually lower the amount of sodium (salt) in the American diet.

27 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

SAFC to invest $6.25M for creating 'Center of Excellence' for dry powder media manufacturing

SAFC®, a member of the Sigma-Aldrich® Group, today announced a $6.25 million investment program to expand its Lenexa, KS, facility and create a global 'Center of Excellence' for the seamless upstream and downstream production of dry powder media and reagents. The investment, part of SAFC's worldwide facilities initiative, is designed to better serve the biopharmaceutical industry by creating 'Centers of Excellence' for manufacturing and supply chain optimization.

27 Apr 2010

AMGA reports success in first two regional meetings on ACOs

The American Medical Group Association announced that the first two meetings in a series of regional meetings focused on accountable care organizations (ACOs) were unqualified successes, drawing healthcare leaders together to network in an intimate setting and to learn from leading medical groups and organized systems of care that are exemplars of the ACO model.

27 Apr 2010

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Ipsen, a global biopharmaceutical group, and Invida Group, the leading healthcare commercialization solutions partner in the Asia Pacific region, announced today an agreement for the exclusive distribution and promotion by Invida of Ipsen's drugs Diphereline® 3.75mg & 11.25mg, Somatuline® Autogel® and Increlex® in selected countries in South-East Asia.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

PPD confirms Japanese approval for Takeda's NESINA NDA

PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.

27 Apr 2010

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.

27 Apr 2010

PPD reports 30% sequential increase in gross authorizations for first-quarter 2010

PPD, Inc. today reported its financial and operating results for the first quarter ended March 31, 2010.

27 Apr 2010

Pharmaceuticals News and Research

States uneasy about impact of Medicaid expansion

Actavis launches Tamsulosin capsules in the U.S.

Expensive generic drugs cost Australia billions

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

ICON reports net revenues of $219 million for first-quarter 2010

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

European commission's FP7 programme allocated euro 6.10 billion

Initiative to lower amount of salt in American diet

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

SAFC to invest $6.25M for creating 'Center of Excellence' for dry powder media manufacturing

AMGA reports success in first two regional meetings on ACOs

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

PPD confirms Japanese approval for Takeda's NESINA NDA

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

PPD reports 30% sequential increase in gross authorizations for first-quarter 2010

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence